Literature DB >> 11850283

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

Rieneke M E van Praag1, Elisabeth C M van Weert, Rolf P G van Heeswijk, Xiao-Jian Zhou, Jean-Pierre Sommadossi, Suzanne Jurriaans, Joep M A Lange, Richard M W Hoetelmans, Jan M Prins.   

Abstract

For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy. While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850283      PMCID： PMC127501          DOI： 10.1128/AAC.46.3.896-899.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Authors:  T N Kakuda; L M Page; P L Anderson; K Henry; T W Schacker; F S Rhame; E P Acosta; R C Brundage; C V Fletcher
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

Authors:  R P van Heeswijk; A I Veldkamp; J W Mulder; P L Meenhorst; F W Wit; J M Lange; S A Danner; N A Foudraine; M O Kwakkelstein; P Reiss; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

Review 3.  The role of therapeutic drug monitoring in treatment of HIV infection.

Authors:  D J Back; S H Khoo; S E Gibbons; C Merry
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

4.  Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.

Authors:  E H Gisolf; R P van Heeswijk; R W Hoetelmans; S A Danner
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

5.  3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; A Meibohm; J H Condra; F T Valentine; D McMahon; C Gonzalez; L Jonas; E A Emini; J A Chodakewitz; R Isaacs; D D Richman
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

6.  High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

Authors:  A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

7.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

8.  The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

Authors:  K H Moore; J E Barrett; S Shaw; G E Pakes; R Churchus; A Kapoor; J Lloyd; M G Barry; D Back
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

9.  Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.

Authors:  R M van Praag; G J Weverling; P Portegies; S Jurriaans; X J Zhou; M L Turner-Foisy; J P Sommadossi; D M Burger; J M Lange; R M Hoetelmans; J M Prins
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

10.  Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

Authors:  G J Weverling; J M Lange; S Jurriaans; J M Prins; V V Lukashov; D W Notermans; M Roos; H Schuitemaker; R M Hoetelmans; S A Danner; J Goudsmit; F de Wolf
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177
View more
  20 in total

1.  Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

Authors:  Brookie M Best; Peter P Koopmans; Scott L Letendre; Edmund V Capparelli; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Gilbert Mbeo; J Allen McCutchan; David M Simpson; Richard Haubrich; Ronald Ellis; Igor Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-23       Impact factor: 5.790

2.  Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

Authors:  Emilio L Streck; Giselli Scaini; Gislaine T Rezin; Jeverson Moreira; Celine M Fochesato; Pedro R T Romão
Journal:  Metab Brain Dis       Date:  2008-09-24       Impact factor: 3.584

3.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

4.  Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-27       Impact factor: 2.745

5.  Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT- or 3TC-induced endothelial dysfunction.

Authors:  Mitzi Glover; Valeria Y Hebert; Krystle Nichols; Stephen Y Xue; Taylor M Thibeaux; James A Zavecz; Tammy R Dugas
Journal:  Antiviral Res       Date:  2014-09-27       Impact factor: 5.970

Review 6.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

7.  Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice.

Authors:  Pedro R T Romão; Joelson C Lemos; Jeverson Moreira; Gisele de Chaves; Morgana Moretti; Adalberto A Castro; Vanessa M Andrade; Carina R Boeck; João Quevedo; Elaine C Gavioli
Journal:  Neurotox Res       Date:  2009-12-10       Impact factor: 3.911

Review 8.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

9.  Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.

Authors:  A K Hemanth Kumar; Geetha Ramachandran; S Rajasekaran; C Padmapriyadarsini; G Narendran; S Anitha; Sudha Subramanyam; V Kumaraswami; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2009-10       Impact factor: 2.375

Review 10.  A review of the pharmacokinetics of abacavir.

Authors:  Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.